<DOC>
	<DOCNO>NCT00774319</DOCNO>
	<brief_summary>The purpose trial compare two different treatment fit patient head neck cancer : All patient give induction-chemotherapy ( docetaxel , cisplatin , 5-FU ) . Subsequently patient randomise two group : - The first group receive neo-adjuvant chemotherapy ( 'high ' dose cisplatin ) conventional radiotherapy - The second group receive neo-adjuvant chemotherapy ( 'low ' dose cisplatin ) accelerate radiotherapy .</brief_summary>
	<brief_title>TPF Induction With Concomitant Chemoradiation Treat Patients With Head Neck Cancer</brief_title>
	<detailed_description>Induction Chemotherapy TPF ( arm A B ) : Docetaxel 75 mg/m2 iv day 1 , Cisplatin 75 mg/ m2 iv day 1 , 5-FU 750 mg/ m2/day iv continuous infusion ( Hickman port cath ) day 1-5 ; prophylactic G-CSF This cycle repeat every 21 day maximum 4 cycle . Clinical evaluation cycle radiological evaluation 2 cycle take place . In case PD SD ( 2 cycle ) minor response ( decrease measurable disease baseline ) concomitant chemoradiotherapy start per protocol . Surgery The investigator centre decide neck surgery residual tumor</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histology stag disease Histologically cytologically proven nonmetastatic locally advanced HNSCC , stage III IV , concomitant chemoradiotherapy would standard therapy Patients include either irresectable disease concomitant chemoradiotherapy choose organ preservation Measurable disease Primary site : oral cavity , oropharynx , hypopharynx larynx General condition Written inform consent Age &gt; 18 year â‰¤ 65 year WHO performance status 01 Adequate bone marrow function ( WBC &gt; 3.0 x 109/L , platelet &gt; 100 x 109/L , Hb &gt; 6 mmol/L ) Adequate hepatic function : total bilirubin &lt; 1 . 5 x upper normal limit , ASAT ALAT &lt; 2.5 x upper normal limit Adequate renal function : calculate creatinin clearance &gt; 60ml/min . ( CockcroftGault formula ) Other Expected adequacy followup . General condition Active alcohol addiction Admission COPD last 12 month Weight loss &gt; 10 % 3 month entry Pregnancy lactation Patients ( M/F ) reproductive potential implementing adequate contraceptive measure Prior current history Prior surgery , radiotherapy chemotherapy tumor Serious concomitant disease prevent safe administration chemotherapy and/or radiotherapy likely interfere study assessment Serious active infection Other malignancy past 5 year exception adequately treat carcinoma situ cervix , squamous basal cell carcinoma skin Concomitant treatment Concomitant ( within 4 week randomisation ) administration experimental drug investigation Concurrent treatment anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>HNSCC</keyword>
	<keyword>neo Adjuvant</keyword>
	<keyword>Chemoradiation therapy</keyword>
	<keyword>TPF</keyword>
</DOC>